Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease

Javier Escaned1*, MD, PhD; Adrian Banning2, MD, PhD; Vasim Farooq3, MBChB, MRCP, PhD; Mauro Echavarria-Pinto1, MD; Yoshinobu Onuma4, MD, PhD; Nicola Ryan1, MB, BCh; Rafael Cavalcante5, MD, PhD; Carlos M. Campos5,6, MD; Bojan M. Stanetic5,7, MD; Yuki Ishibashi5, MD, PhD; Pannipa Suwannasom5,8, MD; Arie-Pieter Kappetein5, MD, PhD; David Taggart2, MD; Marie-Angèle Morel4, BSc; Gerrit-Anne van Es4, PhD; Patrick W. Serruys9, MD, PhD; on behalf of the SYNTAX II Study Group